- Home
- HURA vs LIEN Comparison
HURA vs LIEN Comparison
Compare HURA & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- LIEN
- Stock Information
- Founded
- HURA 2009
- LIEN 2021
- Country
- HURA United States
- LIEN United States
- Employees
- HURA N/A
- LIEN N/A
- Industry
- HURA
- LIEN
- Sector
- HURA
- LIEN
- Exchange
- HURA Nasdaq
- LIEN NYSE
- Market Cap
- HURA 246.9M
- LIEN 292.1M
- IPO Year
- HURA N/A
- LIEN 2022
- Fundamental
- Price
- HURA $4.39
- LIEN $12.35
- Analyst Decision
- HURA
- LIEN
- Analyst Count
- HURA 0
- LIEN 0
- Target Price
- HURA N/A
- LIEN N/A
- AVG Volume (30 Days)
- HURA 668.3K
- LIEN 6.7K
- Earning Date
- HURA 02-15-2025
- LIEN 11-07-2024
- Dividend Yield
- HURA N/A
- LIEN 8.83%
- EPS Growth
- HURA N/A
- LIEN N/A
- EPS
- HURA N/A
- LIEN 0.67
- Revenue
- HURA N/A
- LIEN $12,681,914.00
- Revenue This Year
- HURA N/A
- LIEN N/A
- Revenue Next Year
- HURA N/A
- LIEN N/A
- P/E Ratio
- HURA N/A
- LIEN $18.52
- Revenue Growth
- HURA N/A
- LIEN 22.94
- 52 Week Low
- HURA $2.84
- LIEN $7.29
- 52 Week High
- HURA $14.60
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- LIEN N/A
- Support Level
- HURA N/A
- LIEN N/A
- Resistance Level
- HURA N/A
- LIEN N/A
- Average True Range (ATR)
- HURA 0.00
- LIEN 0.00
- MACD
- HURA 0.00
- LIEN 0.00
- Stochastic Oscillator
- HURA 0.00
- LIEN 0.00
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.